tqh3821 + methotrexate

**tqh3821 + methotrexate** is an investigational **combination therapy** that includes TQH3821, a small molecule IRAK4 (Interleukin-1 receptor-associated kinase 4) inhibitor, and methotrexate, a well-established disease-modifying anti-rheumatic drug (DMARD) that acts as an antimetabolite and antifolate agent. The combination has been evaluated in clinical trials for safety, tolerability, and pharmacokinetics in healthy subjects and patients with rheumatoid arthritis, with TQH3821 expected to modulate inflammatory and immune responses by inhibiting IRAK4 pathways, and methotrexate providing its established anti-inflammatory and immunosuppressive effects. The combination aimed to provide a novel approach to immune-mediated inflammatory diseases, specifically rheumatoid arthritis. TQH3821 was being developed by Chia Tai Tianqing Pharmaceutical Group (CTTQ), and the combination was tested for drug-drug interactions and synergistic therapeutic benefit in both phase 1 and phase 2 trials, but development appears to have been discontinued after phase 2[1][2][4][6][8].

Other names

tqh3821 + methotrexate